Nuvalent, Inc.NUVL
NasdaqGS•Healthcare•Biotechnology
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Nuvalent, Inc. (NUVL) reported trailing twelve months revenue of $0 as of March 2026, a NaN% decline year-over-year. Quarterly revenue reached $0, reflecting a contraction in sales.
Nuvalent, Inc. reported a TTM net loss of $450.07M, with quarterly EBITDA of $-119.41M. The operating margin contracted from -9481200000.0% to -11940700000.0%, suggesting rising cost pressures or pricing headwinds.
The spread between operating margin (-11940700000.0%) and net margin (-10927900000.0%) indicates tight cost control with minimal non-operating drag. Net margin has narrowed from -8458200000.0% a year ago, reflecting increased costs or interest expense.
NUVL trades at a P/S of N/A. The price-to-book ratio of 8.3x indicates a significant premium over book value.
The company reported negative free cash flow of $-92.40M, indicating cash consumption over the period. The balance sheet shows $1.33B in total assets with no in long-term debt against $1.17B in stockholders equity. Data based on the most recent quarterly reports.
Competitive analysis based on 20 quarters of fundamental data
Operating margins are under pressure, averaging -9518675000.0%. The business may lack pricing power or face rising costs.'
ROE is low or negative, suggesting limited competitive advantage or capital allocation challenges.
Only 0 of the last 8 quarters had positive FCF — the business may require external capital to sustain operations.
Revenue has been flat or declining over recent quarters, which may indicate eroding demand or competitive pressure.
Data-driven red flags and warnings across 20 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.
Limited debt-to-equity data available.
Revenue is stable or growing over recent quarters — demand appears durable.
The last 8 consecutive quarters had negative FCF — the company is burning cash and may need external funding.
Shares outstanding increased 21.8% — significant dilution, likely from stock compensation or capital raises.